Newsroom

Biotechnology

Explore the latest breakthroughs and trends in the Biotechnology sector with our newsroom. From cutting-edge innovations in gene therapy and biopharmaceuticals to advancements in medical research and regulatory updates, we provide essential insights into the scientific developments shaping the future of healthcare and life sciences.


Latest Press Releases

Dyadic to Report Second Quarter 2020 Financial Results on Thursday, August 13, 2020
BiotechnologyCompany Update

Dyadic to Report Second Quarter 2020 Financial Results on Thursday, August 13, 2020

July 30, 2020 4:00 PM

JUPITER, FL / ACCESSWIRE / July 30, 2020 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for quarter ended June 30, 2020 after the...

Read more
Xenetic Biosciences, Inc. Strengthens Scientific Advisory Board with Two Key Appointments
BiotechnologyCompany Update

Xenetic Biosciences, Inc. Strengthens Scientific Advisory Board with Two Key Appointments

July 30, 2020 8:05 AM

Jia Xie, PhD, a prominent researcher at Scripps Research responsible for inventing a collection of new technologies for antibody drug discovery and cell therapy Alexey V. Stepanov, PhD, a leading research expert in developing personalized therapeutic tools for lymphoproliferative disease using cell therapy Appointments bring valuable expertise to Scientific Advisory Board as the Company works to advance development of XCART through...

Read more
Edesa Biotech Files IND Application for Phase 2/3 COVID-19 Study
BiotechnologyCompany Update

Edesa Biotech Files IND Application for Phase 2/3 COVID-19 Study

July 30, 2020 7:45 AM

TORONTO, ON / ACCESSWIRE / July 30, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 2/Phase 3 clinical study of its investigational drug, EB05, for the treatment of hospitalized COVID-19 patients. The company recently received expedited approval to begin the Phase 2/3 study...

Read more
Afecta Pharmaceuticals Announces Publication of Studies on Treatment of Malignant Melanoma
BiotechnologyCompany Update

Afecta Pharmaceuticals Announces Publication of Studies on Treatment of Malignant Melanoma

July 28, 2020 6:25 PM

IRVINE, CA / ACCESSWIRE / July 28, 2020 / Afecta Pharmaceuticals announces publication of a new study in collaboration with colleagues at the University of California at Irvine (UCI) that identifies novel mechanisms of action of Luteolin, a naturally occurring chemical found in several fruits and vegetables that inhibits growth of malignant melanoma in vitro and in vivo. The paper published in the journal Biochemical Pharmacology...

Read more
Binovi Provides Further Update to Its Filing of Annual and First Quarter Financial Statements
BiotechnologyCompany Update

Binovi Provides Further Update to Its Filing of Annual and First Quarter Financial Statements

July 28, 2020 5:30 PM

TORONTO and  NEW YORK / ACCESSWIRE / July 28, 2020 /  Binovi Technologies Corp., (Binovi) (OTCQB:BNVIF)(TSXV:VISN ), a leader in neuro-vision performance technology announces that further to its news release dated June 29, 2020 the Company is continuing to rely on temporary blanket relief granted by Canadian securities regulators, allowing reporting issuers to extend certain continuous disclosure filing deadlines by 45 days. Binovi reconfirms...

Read more
Canam Biotech Inc. Applies for Temporary Exemption from Filing Its Quarterly Report for the Period Ended May 31, 2020 (Q2)
BiotechnologyCompany UpdateRegulatory

Canam Biotech Inc. Applies for Temporary Exemption from Filing Its Quarterly Report for the Period Ended May 31, 2020 (Q2)

July 28, 2020 2:15 PM

VANCOUVER, BC / ACCESSWIRE / July 28, 2020 / Canam Biotech Inc. (formerly, HemaGenetics Technologies Corp.) (the "Company"), due to ongoing non-essential business shut down for COVID-19 measures taken by the Province of British Columbia, is relying on the exemption in BC Instrument 51-517 issued by the British Columbia Securities Commission and the reciprocating similar instrument issued by the Alberta Securities Commission allowing it to delay...

Read more
Experion Holdings Announces New Chairman of the Board
BiotechnologyCompany UpdateManagement Changes

Experion Holdings Announces New Chairman of the Board

July 28, 2020 8:45 AM

VANCOUVER, BC / ACCESSWIRE / July 28, 2020 / Experion Holdings Ltd. (the "Company" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31) is pleased to announce the appointment of Mr. Sean MacNeil as Chairman of the Board. Mr. MacNeil commented, "I would like to thank our shareholders and the board for giving me this opportunity to lead Experion. In 2013 Bob Howard and I proudly founded Experion and since that time the cannabis industry...

Read more
Omnicanna Joins the Cannabis Science CSi-EDP, Officially Showcasing Exclusive Industrial Hemp Online Real-Time Trading Technology
BiotechnologyCompany Update

Omnicanna Joins the Cannabis Science CSi-EDP, Officially Showcasing Exclusive Industrial Hemp Online Real-Time Trading Technology

July 28, 2020 8:30 AM

RALEIGH, NC / ACCESSWIRE / July 28, 2020 / Omnicanna Health Solutions, Inc. (OTC PINK:ENDO), a U.S. Company specializing in hemp formulation-based health and wellness solutions, is pleased to announce Omnicanna joins in the Cannabis Science CSi-EDP, officially showcasing exclusive revolutionary industrial hemp online trading technology. This technology includes industrial, medical, wholesale, and retail products and consumer goods. Omnicanna...

Read more
SignPost Cancer Dx Inc. Files Provisional Patent
BiotechnologyCompany Update

SignPost Cancer Dx Inc. Files Provisional Patent

July 28, 2020 8:00 AM

DNA Methylation Multivariate Biomarkers Offers 98% Specificity and Sensitivity ONTARIO, CANADA / ACCESSWIRE / July 28, 2020 / SignPost Cancer Dx Inc. ("SignPost" or "company"), a company developing an advanced molecular diagnostic test to identify invasive breast cancer, is pleased to announce the filing of a provisional patent for the company's lead diagnostic test - BreastDefense. SignPost's goal is to create the world's most accurate...

Read more
Tetra Bio-Pharma’s Management Provides Corporate Update on QIXLEEF(TM) & CAUMZ(TM) Drug Development Activities
BiotechnologyCompany Update

Tetra Bio-Pharma’s Management Provides Corporate Update on QIXLEEF(TM) & CAUMZ(TM) Drug Development Activities

July 28, 2020 8:00 AM

Resumption of its PLENITUDE© clinical trial on-time; CAUMZ™ manufacturing set to begin in USA to allow start of clinical trials; QIXLEEF™ metabolite mapping study to be complete in Q3 2020 OTTAWA / ACCESSWIRE / July 28, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSXV:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced that the long awaited resumption of its PLENITUDE©...

Read more
Nascent Biotech Announces Collaboration with Syracuse University - Advancing COVID-19 Research
BiotechnologyCompany Update

Nascent Biotech Announces Collaboration with Syracuse University - Advancing COVID-19 Research

July 28, 2020 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / July 28, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO), announced today it has entered into a research collaboration with Syracuse University to further the development of Pritumumab, a unique monoclonal antibody that binds to cell-surface vimentin, for potential use in COVID-19 treatment. Alison Patteson, an assistant professor of physics at Syracuse University, will test to see if Pritumumab has the potential to...

Read more
Memgen Announces Addition of Leading Vaccine Expert to Scientific Advisory Board
BiotechnologyManagement Changes

Memgen Announces Addition of Leading Vaccine Expert to Scientific Advisory Board

July 28, 2020 6:00 AM

HOUSTON, TX / ACCESSWIRE / July 28, 2020 / ​​Memgen, Inc., a private biotechnology company developing innovative immune-based drugs for the control of infectious diseases and cancer, announced today that Dr. Thomas Monath, a world-renowned virologist and vaccinologist, has joined the Company's Scientific Advisory Board. The addition of Dr. Monath highlights the potential of the Company's vaccine program as it advances its COVID-19 vaccine...

Read more
Tetra Bio-Pharma Provides Management Update on Pharma Focus
BiotechnologyCompany Update

Tetra Bio-Pharma Provides Management Update on Pharma Focus

July 27, 2020 8:00 AM

OTTAWA, CANADA / ACCESSWIRE / July 27, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSXV:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is providing its shareholders with a management update on the Company's Annual General Meeting (AGM) of shareholders commitment to be concentrating 100% of its efforts on its drug development programs with the current focus on ARDS, Plenitude© and Reborn©. Tetra...

Read more
Hancock Jaffe Receives Permission to Proceed with First-in-Human CoreoGraft Study
BiotechnologyCompany Update

Hancock Jaffe Receives Permission to Proceed with First-in-Human CoreoGraft Study

July 23, 2020 8:30 AM

Patient Selection to Begin Immediately for CoreoGraft Study IRVINE, CA / ACCESSWIRE / July 23, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Italian Hospital Asuncion in Paraguay has given the Company permission to proceed with the CoreoGraft first-in-human study. The study had been delayed due to constraints at the hospital caused by the...

Read more
Pieris Pharmaceuticals Announces Oral Presentation of Phase 1 Data for 4-1BB/HER2 Bispecific PRS-343 at European Society for Medical Oncology (ESMO) Virtual Congress 2020
BiotechnologyCompany Update

Pieris Pharmaceuticals Announces Oral Presentation of Phase 1 Data for 4-1BB/HER2 Bispecific PRS-343 at European Society for Medical Oncology (ESMO) Virtual Congress 2020

July 23, 2020 8:00 AM

BOSTON, MA / ACCESSWIRE / July 23, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that the Company will present phase 1 dose-escalation monotherapy and combination with atezolizumab data for PRS-343, a 4-1BB/HER2 bispecific for the treatment of...

Read more
Midatech Pharma PLC Announces Corporate Update & Formal Sale Process Termination
BiotechnologyRegulatory

Midatech Pharma PLC Announces Corporate Update & Formal Sale Process Termination

July 23, 2020 2:00 AM

ABINGDON, OXFORDSHIRE / ACCESSWIRE / July 23, 2020 / Midatech (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces it has terminated the formal sale process initiated by the Company on 20 April 2020. The formal sale process, as referred to in the City Code on Takeovers and Mergers (the "Code"), granted dispensations from Rule 2 of the Code such that any...

Read more
Hancock Jaffe Laboratories Announces Closings of $6.2 Million Offerings Including Full Exercise of Over-Allotment Option
BiotechnologyCompany Update

Hancock Jaffe Laboratories Announces Closings of $6.2 Million Offerings Including Full Exercise of Over-Allotment Option

July 21, 2020 4:01 PM

IRVINE, CA / ACCESSWIRE / July 21, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced the closings of an underwritten public offering, the full exercise of the underwriter's over-allotment option, and a private placement, for total gross proceeds of approximately $6.2 million, prior to deducting underwriting discounts, placement agent fees, and offering...

Read more
Pieris Pharmaceuticals Announces Partial Clinical Hold On PRS-343
BiotechnologyCompany Update

Pieris Pharmaceuticals Announces Partial Clinical Hold On PRS-343

July 20, 2020 4:05 PM

FDA requested a confirmatory laboratory-based in-use and compatibility study before enrolling new patients Currently-enrolled patients may continue to receive PRS-343 In its telephonic communication, FDA did not cite any adverse events in connection with its request Company reiterates intent to initiate planned phase 2 study of PRS-343 in HER2-positive gastric cancer later this year pending successful completion of the requested...

Read more
GB Sciences Announces Issuance of US Patent for Its Proprietary Pain Formulations for the 560 Billion Dollar Chronic Pain Treatment Market
BiotechnologyCompany Update

GB Sciences Announces Issuance of US Patent for Its Proprietary Pain Formulations for the 560 Billion Dollar Chronic Pain Treatment Market

July 20, 2020 9:00 AM

LAS VEGAS, NV / ACCESSWIRE / July 20, 2020 / GB Sciences, Inc. (OTCQB:GBLX), announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,709,670 entitled "Myrcene-Containing Complex Mixtures Targeting TRPV1" on July 14, 2020. This US patent is assigned to GBS Global Biopharma (GBS), Inc., GB Sciences' Canadian entity. The US Patent protects methods of using GBS' proprietary Myrcene-Containing Complex...

Read more
Apollo Endosurgery Announces $25 Million Equity Financing, Solar Loan Amendment and Second Quarter Business Update
BiotechnologyCompany Update

Apollo Endosurgery Announces $25 Million Equity Financing, Solar Loan Amendment and Second Quarter Business Update

July 20, 2020 6:30 AM

AUSTIN, TX / ACCESSWIRE / July 20, 2020 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that it has entered into definitive agreements for a $25 million equity financing. Concurrently, Apollo entered into an amendment to its Loan and Security Agreement, dated March 2019, with Solar Capital Ltd. ("Solar"), to modify certain...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers • July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie • July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers • July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers • June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers • June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers • June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?